REFERENCES
1. Ojeda P, Sastre J, Olaguibel JM, Chivato T, investigators
participating in the National Survey of the Spanish Society of A,
Clinical Immunology A. Alergologica 2015: A National Survey on Allergic
Diseases in the Adult Spanish Population. J Investig Allergol Clin
Immunol. 2018;28(3):151-164.
2. Mayorga C, Fernandez TD, Montanez MI, Moreno E, Torres MJ. Recent
developments and highlights in drug hypersensitivity. Allergy.2019;74(12):2368-2381.
3. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on
drug allergy. Allergy. 2014;69(4):420-437.
4. Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of
drug hypersensitivity reactions: similarities and differences between
Europe and North America. Clinical and translational allergy.2017;7:7.
5. Tanno LK, Torres MJ, Castells M, Demoly P, Joint Allergy A. What can
we learn in drug allergy management from World Health Organization’s
international classifications? Allergy. 2018;73(5):987-992.
6. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate
reactions to beta-lactam antibiotics. Allergy.2004;59(11):1153-1160.
7. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General
considerations for skin test procedures in the diagnosis of drug
hypersensitivity. Allergy. 2002;57(1):45-51.
8. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the
diagnosis of drug hypersensitivity reactions: general considerations.Allergy. 2003;58(9):854-863.
9. Pichler WJ. Delayed drug hypersensitivity reactions. Annals of
internal medicine. 2003;139(8):683-693.
10. Fernandez TD, Mayorga C, Torres MJ, et al. Cytokine and chemokine
expression in the skin from patients with maculopapular exanthema to
drugs. Allergy. 2008;63(6):712-719.
11. Chaves P, Torres MJ, Aranda A, et al. Natural killer-dendritic cell
interaction in lymphocyte responses in hypersensitivity reactions to
betalactams. Allergy. 2010;65(12):1600-1608.
12. Pichler WJ. Immune pathomechanism and classification of drug
hypersensitivity. Allergy. 2019;74(8):1457-1471.
13. Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug
hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group
position paper. Allergy. 2016;71(8):1103-1134.
14. Mayorga C, Ebo DG, Lang DM, et al. Controversies in drug allergy: In
vitro testing. J Allergy Clin Immunol. 2019;143(1):56-65.
15. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69
upregulation on T cells as an in vitro marker for delayed-type drug
hypersensitivity. Allergy. 2008;63(2):181-188.
16. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of
the lymphocyte transformation test in the diagnosis of drug sensitivity:
dependence on its timing and the type of drug eruption. Allergy.2007;62(12):1439-1444.
17. Pichler WJ, Tilch J. The lymphocyte transformation test in the
diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-820.
18. Luque I, Leyva L, Jose Torres M, et al. In vitro T-cell responses to
beta-lactam drugs in immediate and nonimmediate allergic reactions.Allergy. 2001;56(7):611-618.
19. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement
of dendritic cells in delayed-type hypersensitivity reactions to
beta-lactams. J Allergy Clin Immunol. 2006;118(4):949-956.
20. Rozieres A, Hennino A, Rodet K, et al. Detection and quantification
of drug-specific T cells in penicillin allergy. Allergy.2009;64(4):534-542.
21. Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are
effective during the acute phase of delayed-type drug hypersensitivity
reactions. The British journal of dermatology.2013;168(3):539-549.
22. Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata
TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson
syndrome - alternatives for lymphocyte transformation test. Clin
Exp Allergy. 2013;43(9):1027-1037.
23. Sachs B, Erdmann S, Malte Baron J, Neis M, al Masaoudi T, Merk HF.
Determination of interleukin-5 secretion from drug-specific activated ex
vivo peripheral blood mononuclear cells as a test system for the in
vitro detection of drug sensitization. Clin Exp Allergy.2002;32(5):736-744.
24. Mayorga C, Dona I, Perez-Inestrosa E, Fernandez TD, Torres MJ. The
Value of In Vitro Tests to DiminishDrug Challenges. International
journal of molecular sciences. 2017;18(6).
25. Ebo DG, Leysen J, Mayorga C, Rozieres A, Knol EF, Terreehorst I. The
in vitro diagnosis of drug allergy: status and perspectives.Allergy. 2011;66(10):1275-1286.
26. Castrejon JL, Berry N, El-Ghaiesh S, et al. Stimulation of human T
cells with sulfonamides and sulfonamide metabolites. J Allergy
Clin Immunol. 2010;125(2):411-418 e414.
27. Antunez C, Barbaud A, Gomez E, et al. Recognition of iodixanol by
dendritic cells increases the cellular response in delayed allergic
reactions to contrast media. Clinical and experimental allergy :
journal of the British Society for Allergy and Clinical Immunology.2011;41(5):657-664.
28. Lopez S, Torres MJ, Rodriguez-Pena R, et al. Lymphocyte
proliferation response in patients with delayed hypersensitivity
reactions to heparins. The British journal of dermatology.2009;160(2):259-265.
29. Demoly P, Bousquet J. Drug allergy diagnosis work up.Allergy. 2002;57 Suppl 72:37-40.
30. Aguirre C, Garcia M. [Causality assessment in reports on adverse
drug reactions. Algorithm of Spanish pharmacovigilance system].Med Clin (Barc). 2016;147(10):461-464.
31. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for
systemically administered drugs – an ENDA/EAACI Drug Allergy Interest
Group position paper. Allergy. 2013;68(6):702-712.
32. Barbaud A, Goncalo M, Bruynzeel D, Bircher A, European Society of
Contact D. Guidelines for performing skin tests with drugs in the
investigation of cutaneous adverse drug reactions. Contact
dermatitis. 2001;45(6):321-328.
33. Chiriac AM, Rerkpattanapipat T, Bousquet PJ, Molinari N, Demoly P.
Optimal step doses for drug provocation tests to prove beta-lactam
hypersensitivity. Allergy. 2017;72(4):552-561.
34. Gomez E, Diaz-Perales A, Tordesillas L, et al. Effect of Pru p 3 on
dendritic cell maturation and T-lymphocyte proliferation in peach
allergic patients. Ann Allergy Asthma Immunol. 2012;109(1):52-58.
35. Fernandez-Santamaria R, Palomares F, Salas M, et al. Expression of
the Tim3-galectin-9 axis is altered in drug-induced maculopapular
exanthema. Allergy. 2019;74(9):1769-1779.
36. Torres MJ, Adkinson NF, Jr., Caubet JC, et al. Controversies in Drug
Allergy: Beta-Lactam Hypersensitivity Testing. The journal of
allergy and clinical immunology In practice. 2019;7(1):40-45.
37. Martin M, Wurpts G, Ott H, et al. In vitro detection and
characterization of drug hypersensitivity using flow cytometry.Allergy. 2010;65(1):32-39.
38. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the
diagnosis of drug allergy: sensitivity and specificity. Clin Exp
Allergy. 1997;27(2):175-181.
39. Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in
cutaneous drug eruptions. Clin Exp Allergy. 2001;31(9):1398-1408.
40. Whitaker P, Meng X, Lavergne SN, et al. Mass spectrometric
characterization of circulating and functional antigens derived from
piperacillin in patients with cystic fibrosis. Journal of
immunology. 2011;187(1):200-211.
41. Zawodniak A, Lochmatter P, Yerly D, et al. In vitro detection of
cytotoxic T and NK cells in peripheral blood of patients with various
drug-induced skin diseases. Allergy. 2010;65(3):376-384.
42. Kuechler PC, Britschgi M, Schmid S, Hari Y, Grabscheid B, Pichler
WJ. Cytotoxic mechanisms in different forms of T-cell-mediated drug
allergies. Allergy. 2004;59(6):613-622.
43. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for
disseminated keratinocyte death in Stevens-Johnson syndrome and toxic
epidermal necrolysis. Nature medicine. 2008;14(12):1343-1350.